NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer [ID3757]

Stakeholder list

Consultees	Commentators (no right to submit or appeal)
Company • Bristol-Myers Squibb (Nivolumab) Patient/carer groups • Asthma and Lung UK • Black Health Agency for Equality • Cancer Black Care • Cancer Equality • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Roy Castle Lung Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • UK Lung Cancer Coalition Professional groups • Association of Cancer Physicians • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Thoracic Oncology Group • British Thoracic Society • Cancer Research UK • Lung Cancer Nursing UK • National Heart and Lung Institute • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association for Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Comparator companies • Accord Healthcare (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, pemetrexed, vinorelbine) • Aspire Pharma (pemetrexed) • Dr. Reddy's Laboratories (pemetrexed) • Eli Lilly (pemetrexed) • Genus Pharmaceuticals (pemetrexed) • Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) • Medac (vinorelbine) • Mylan (pemetrexed) • Pfizer (pemetrexed) • Pierre Fabre (vinorelbine) • Roche Products Limited (atezolizumab) • Sandoz (cisplatin, pemetrexed)

© National Institute for Health and Care Excellence 2022. All rights reserved.

Consultees	Commentators (no right to submit or appeal)
• Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social Care • NHS England • NHS North Central London Clinical Commissioning Group • NHS Nottingham and Nottinghamshire CCG • Welsh Government	• Seacross Pharmaceuticals (docetaxel, pemetrexed, paclitaxel) • Sun Pharma (gemcitabine, pemetrexed) • Teva UK (paclitaxel) • Zentiva (pemetrexed) <u>Relevant research groups</u> • Cochrane Lung Cancer Group • Cochrane UK • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research <u>Associated Public Health Groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Draft Guidance (FDG).
All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

[1]Non-company consultees are invited to submit statements relevant to the group they are representing.

© National Institute for Health and Care Excellence 2022. All rights reserved.

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

© National Institute for Health and Care Excellence 2022. All rights reserved.